Knickelbein et al., 1996
Important safety considerations include: Pancreatitis risk : If you develop severe, persistent abdominal pain that may radiate to your back, with or without vomiting, stop taking the medication and seek urgent medical attention Gallbladder disease : Sudden pain in the upper right abdomen, fever, or yellowing of the skin/eyes requires urgent medical review GLP-1 medications are not recommended in people with severe gastrointestinal disease, including severe gastroparesis [10] [11] Clinical considerations include: Starting with the lowest available dose and titrating slowly Monitoring symptom patterns carefully during initiation Distinguishing between temporary side effects (which often lessen over weeks) and persistent symptom changes Adjusting dietary intake, particularly meal size and composition Most gastrointestinal side effects of GLP-1 medications are dose-dependent and tend to diminish over time as the body adapts

It is by no means an overstatement to say that this approach was wildly successful in unlocking GLP-1s therapeutic potential
Yu J, Shan Z, Chong W, Mao J, Geng Y, Zhang C et al
You may also like Product Description CJC-1295 Without DAC + Ipamorelin CJC-1295 Without DAC + Ipamorelin is the most widely studied dual-receptor growth hormone secretagogue combination in pre-clinical research pairing Modified GRF (1-29), a tetra-substituted GHRH receptor agonist, with Ipamorelin, the first selective GHS-R1a (ghrelin receptor) agonist, to simultaneously engage two entirely distinct and complementary pituitary signalling pathways